IL-7

IsoPlexis Announces First APAC Publication, Illustrating Early Impact of Codeplex Platform

Retrieved on: 
Tuesday, September 13, 2022
CodePlex, Adoption, The Scientist (magazine), Health, Risk, Phenotype, Publication, Company, Mouse, IL-7, Proteome, CD19, CEO, Cell, Nasdaq, GLOBE, SEC, HIV disease progression rates, Shanghai Institute of Technology, Scientific Reports, Isoplexis, Vaccine, Fierce, Hematology

With the recent establishment of a regional headquarters in Shanghai, IsoPlexis has strengthened its capability to support and equip customers in the APAC region, enabling groundbreaking innovation.

Key Points: 
  • With the recent establishment of a regional headquarters in Shanghai, IsoPlexis has strengthened its capability to support and equip customers in the APAC region, enabling groundbreaking innovation.
  • The researchers observed that in mice treated with CAR-T cells, cytokine expression measured with IsoPlexis CodePlex platform suggested that IL-7 secretion promoted a Th1 functional phenotype to drive anti-tumor activity more effectively.
  • This initial data generated using IsoPlexis CodePlex solution indicates that the platform can provide key insights into cytokine signatures of CAR-T products to characterize function for improved persistence and potency.
  • This first APAC publication validates IsoPlexis' platform as a powerful tool that provides customers with a new layer of proteomic information, said Jason Ou, President/General Manager, APAC Region at IsoPlexis.

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases

Retrieved on: 
Monday, August 15, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, U.S. Securities and Exchange Commission, Multimedia, Risk, Forward-looking statement, Inflammation, Trial of the century, R, IL-7, Autoimmunity, Research, TSLP, Courage, Patient, EBITDA, Instagram, Twitter, Autoimmune disease, Program, Therapy, Safety, Â, Atopic dermatitis, Science, Nasdaq, LinkedIn, Degenerative disease, Bio, Immunity, Pharmacokinetics, Pharmaceutical industry, Vaccine, Facebook, Horizon

Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.

Key Points: 
  • Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc (Nasdaq: HZNP), today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
  • Horizon is a leader in the autoimmune and inflammatory disease space and brings to this collaboration both the resources and experience of a pharmaceutical company and the speed and agility of a biotech, said Michael Broxson, chief executive officer of Q32 Bio.
  • Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases.
  • Q32 Bio is currently conducting a first-in-human, Phase 1, ascending dose (SAD/MAD) clinical study of ADX-097 for the treatment of complement disorders.

Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, Risk, Forward-looking statement, Inflammation, Trial of the century, R, IL-7, Autoimmunity, Research, TSLP, Courage, Patient, EBITDA, Instagram, Twitter, Autoimmune disease, Horizon Therapeutics, Program, Therapy, Safety, Atopic dermatitis, Science, LinkedIn, Degenerative disease, Immunity, Pharmacokinetics, Pharmaceutical industry, Vaccine, Facebook, Horizon

and DUBLIN, Aug. 15, 2022 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc(Nasdaq: HZNP),today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.

Key Points: 
  • and DUBLIN, Aug. 15, 2022 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Horizon Therapeutics plc(Nasdaq: HZNP),today announced that they have entered into a collaboration and option agreement to develop ADX-914 for the treatment of autoimmune diseases.
  • "Horizon is a leader in the autoimmune and inflammatory disease space and brings to this collaboration both the resources and experience of a pharmaceutical company and the speed and agility of a biotech," saidMichael Broxson, chief executive officer of Q32 Bio.
  • "We are very pleased to begin our collaboration with Q32 to advance ADX-914 through the next phase of clinical development," saidElizabeth H.Z.
  • Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases.

Medikine Initiates First Clinical Trial of its Lead Program, an Interleukin-7 Mimetic, Under Management Team with Expertise in Next-Generation Cytokine Drug Discovery and Development

Retrieved on: 
Tuesday, July 19, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IL-7, Half-life, Memory, Pharmacology, Biology, Erythropoietin, Thrombopoietin, Disease, Acquisition, Cancer, Innovation, Infection, Science, Degenerative disease, Pharmacokinetics, Safety, Therapy, Engineering, Eli Lilly and Company, Drug discovery, Technology, CD8, Saṃsāra, Sanofi, Maintenance, Bristol Myers Squibb, Human, Survival, Amgen, Cytokine, Research, Board, Health, DRS, CD4, NK, ADAS, TSCM, Clinical trial, Pharmaceutical industry, Vaccine

IL-7 is a cytokine critical for the development and maintenance of T cells, including enhancing generation, function, and survival of memory T cells.

Key Points: 
  • IL-7 is a cytokine critical for the development and maintenance of T cells, including enhancing generation, function, and survival of memory T cells.
  • The company plans to investigate MDK-703 in solid tumors following the completion of the Phase 1 clinical trial in healthy volunteers.
  • Dr. Milla commented, With its versatile drug discovery platform, Medikine is well-positioned to develop transformative therapies for cancer and other serious diseases.
  • In addition to its lead product candidate, MDK-703, Medikine also has identified novel PEPTIKINES that activate the IL-2/15 receptor complex.

OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer

Retrieved on: 
Wednesday, July 13, 2022
Strategic management, Cancer, General manager, HNSCC, OSE, Patient, Ulcerative colitis, Autoimmune disease, ISIN, IL-7, École centrale de Lyon, Tissue, Hepatocellular carcinoma, PD-1, Company, Boehringer Ingelheim, GLOBE, CD28, Immunotherapy, BI, Partnership, Clinical trial, Business development, Science, Engineering, Large-cell lung carcinoma, Inflammation, Roche, COVID-19, Epitope, BMS, RMIT School of Economics, Finance and Marketing, Transplant, Lead, Growth, University, Kharkiv National University of Economics, Innovative Marketing, Mab, Nivolumab, Mnemos EP, Fortification, HCC, Marketing, Sanofi, Immune system, Board, Pancreatic cancer, Fine chemical, Pharmaceutical industry, Vaccine, Pharma, Alliance, EU, Ipsen

NANTES, France, July 13, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately.

Key Points: 
  • NANTES, France, July 13, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately.
  • Dr. Dominique Costantini, Chairwoman of the Board, said: The Board of Directors is very pleased to announce Alexis Vandier as OSE Immunotherapeutics new Chief Executive Officer.
  • I am confident that Alexis Vandier, together with OSEs highly talented team, will continue to build on these achievements and further expand OSE internationally.
  • Alexis Vandier, the new Chief Executive Officer of OSE Immunotherapeutics, commented: I am thrilled to join the OSE team in this new role at a very exciting time.

FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7 for the treatment of Glioblastoma Multiforme

Retrieved on: 
Wednesday, July 13, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NK, HGG, Radiation, Chemoradiotherapy, TRL, NIT, TMZ, Cognition, GBM, Company, Survival, Patient, ODD, Degenerative disease, Society, SITC, Food, Brain, Diagnosis, TTF, PFS, Immunotherapy, Awareness, IL-7, II, FDA, Research, Immune system, Recurrence, Cancer, Infection, Industry, Behavior, CD8, Immunity, Pharmaceutical industry, Medical imaging, Vaccine, Glioblastoma

Dr Se Hwan Yang,Ph.D., President and Chief Executive Officer of NeoImmuneTech, Inc. said: "We are excited that the FDA granted NTI7 an ODD in the treatment of glioblastoma multiforme.

Key Points: 
  • Dr Se Hwan Yang,Ph.D., President and Chief Executive Officer of NeoImmuneTech, Inc. said: "We are excited that the FDA granted NTI7 an ODD in the treatment of glioblastoma multiforme.
  • We look forward to continuing our collaboration with FDA, as we explore the benefits of NT-I7 in treating people with GBM in combination with other anti-cancer treatments, including immunotherapies".
  • [2]Current studies in GBM include study NIT-107 in newly diagnosed GBM patients and study NIT-120 in recurrent GBM patients.
  • [3]
    The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US.

OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting

Retrieved on: 
Thursday, June 23, 2022
Transplant, Immune system, OSE, GLOBE, Fortification, Patient, Ulcerative colitis, Clinical trial, Cancer, Mission statement, Tissue, Mab, Hepatocellular carcinoma, COVID-19, ISIN, Partnership, PD-1, Autoimmune disease, Pancreatic cancer, HCC, Nivolumab, Combined, Epitope, BI, IL-7, HNSCC, Large-cell lung carcinoma, Boehringer Ingelheim, Mnemos EP, Immunotherapy, Inflammation, Holding company, Pharmaceutical industry, Vaccine

NANTES, France, June 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders Meeting were approved as proposed by OSE Immunotherapeutics Board of Directors.

Key Points: 
  • NANTES, France, June 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders Meeting were approved as proposed by OSE Immunotherapeutics Board of Directors.
  • The results of each resolution voted on can be found on the Companys website in the Investor General Shareholders Meeting section: https://ose-immuno.com/en/general-shareholders-meetings/ .
  • They also approved the renewal of the term of office as director of Maryvonne Hiance, Didier Hoch and Nicolas Poirier (director representing the employee shareholders), which expired at this General Meeting, for three years.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

OSE Immunotherapeutics Announces Collaboration with Microsoft

Retrieved on: 
Thursday, June 16, 2022
IL-7, PD-1, Epitope, Mnemos EP, Autoimmune disease, HNSCC, Pancreatic cancer, Inflammation, GLOBE, Large-cell lung carcinoma, Tissue, Intelligence, Technology, Transplant, Microsoft Azure, Ulcerative colitis, Cancer, Azure, Mab, Immune system, ISIN, COVID-19, HCC, BI, Artificial intelligence, Algorithm, Nivolumab, Failure, Patient, Architecture, Microsoft, Immunotherapy, Risk, Antibody, Biotechnology, Company, Research, Boehringer Ingelheim, Ecosystem, Program, Fortification, Hepatocellular carcinoma, Partnership, OSE, Machine learning, AI, Video game, Medical device, Pharmaceutical industry, Vaccine

OSE selected by Microsoft France to join the Biotech Scaler Program launched during Viva Technology, the European Startup and Tech event.

Key Points: 
  • OSE selected by Microsoft France to join the Biotech Scaler Program launched during Viva Technology, the European Startup and Tech event.
  • NANTES, France, June 16, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company is one of the first biotech startup companies selected by Microsoft France to be a privileged partner of its support program for French Biotech & Deeptech Startups.
  • Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics, comments: We are very happy to have been selected by Microsoft to join their Biotech & Deeptech support program and we warmly thank the organizers.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Shelia Violette, Founder and Chief Scientific Officer of Q32 Bio, to Present at the Keystone Symposia "Resolution of Inflammation" Conference

Retrieved on: 
Wednesday, June 8, 2022
Degenerative disease, IL-7, Company, Inflammation, Immunity, Founder, Therapy, Autoimmunity, Complement, Patient, Risk, Trial of the century, TSLP, C3D Toolkit, Tissue, Pharmaceutical industry, Vaccine

WALTHAM, Mass., June 8, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that its Founder and Chief Scientific Officer, Shelia Violette, Ph.D., will present "Targeting Complement in Chronic Inflammatory Disease" at the "Resolution of Inflammation" conference, and is the co-organizer of the "Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies" conference, at the Keystone Symposia on Molecular and Cellular Biology, taking place June 12 through June 16, 2022.

Key Points: 
  • Dr. Violette's presentation will focus on the potential for tissue targeted complement inhibition and the Company's proprietary targeted complement platform.
  • This platform includes ADX-097, a first-in-class tissue directed complement therapeutic with the ability to provide a unique therapeutic approach to restore complement regulation in diseased tissue by targeting C3d.
  • ADX-097 recently entered the clinic as the Company's first-in-human phase 1 clinical study from its pipeline of biologic therapeutic candidates.
  • Q32 Bio is currently conducting a first-in-human, Phase 1, ascending dose (SAD/MAD) clinical study of ADX-097 for the treatment of complement disorders.

OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi® in Immuno-Oncology at ASCO 2022

Retrieved on: 
Monday, May 23, 2022
OSE, IL-7, HCC, Immunotherapy, Annual general meeting, ISIN, BI, Ulcerative colitis, Transplant, Cancer, 2021 Essex County Council election, Patient, Inflammation, PD-1, Society, American Society of Clinical Oncology, COVID-19, HNSCC, Partnership, Hepatocellular carcinoma, Fortification, Autoimmune disease, ASCO, Large-cell lung carcinoma, Mnemos EP, Boehringer Ingelheim, Nivolumab, Immune system, Pancreatic cancer, Epitope, Mab, Tissue, GLOBE, Pharmaceutical industry, Vaccine

NANTES, France, May 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring neoepitope combination Tedopi in various cancer indications at the American Society of Clinical Oncology (ASCO) Annual Meeting , being held June 4 7, 2022 in Chicago.

Key Points: 
  • NANTES, France, May 23, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring neoepitope combination Tedopi in various cancer indications at the American Society of Clinical Oncology (ASCO) Annual Meeting , being held June 4 7, 2022 in Chicago.
  • Other ongoing combination trials sponsored by cooperative clinical research groups in oncology:
    Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
  • Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
  • Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.